FACSIMILE TRANSMISSION Transmission problems: (858) 720-2584





July 15, 2002

FAX RECEIVED

IJUL 15 2002

PETITIONS OFFICE

Broback, Phleger & Harrison LLP 12750 High Bluff Suite 300 San Diego, Callfomla 92130-2081 PHONE 858.720,2500 FAX 858.720,3700

www.brobeck.com

PAGES TO FOLLOW CO	OVER	_1_	USER ID	0454	CMID NUMBER	030639.0043.UTL2
TO RECIPIENT	COMF	PANY		•	TELEPHONE	FAX
Office of Petitions	U.S. Patent and Trademark Office					(703) 308-6916
FROM SENDER	EMAL				TELEPHONE	FAX
Lisa M. McGeehan	LMcGeehan@brobeck.com				(858) 720-2584	(858) 720-3700

Re:

U.S. Application Serial No. 09/554,533 International Application No. PCT/US98/24210

RECEIVED

26 JUL 2002 Legal Starf International Division

PRIVILEGED AND CONFIDENTIAL

All information transmitted hereby is intended only for the use of the addressee(s) named above. If the reader of this message is not the intended recipient or the employee or agent responsible for delivering the message to the intended recipient(s), please note that any distribution or copying of this communication is strictly prohibited. Anyone who receives this communication in error should notify us immediately by telephone and mail the original message to us at the above address.



JUL 1 5 2002

Patent 030639.0043.UTL2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: Beeley et al.

U.S. Application Serial No.: 09/554,533

International Application No.:

PCT/US98/24210

International Filing Date: November 13,

1998

Group Art Unit: To Be Assigned

Examiner: To Be Assigned

For: NOVEL EXENDIN AGONIST

COMPOUNDS

COMMUNICATION

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

This Communication is further to the Transmittal of Missing Requirements, filed with a Petition for Revival of Abandoned Application Under 37 CFR §1.137, and transmitted to the Patent Office on July 11, 2002. In that Transmittal, the Patent Office was "authorized to charge Counsel's Deposit Account No. 50-1273 for any fees required, including the surcharge for providing the oath or declaration later than the appropriate 20 or 30 months from the priority date (37 C.F.R. 1.492(c))."

While not necessary to provide authorization for payment of the surcharge in view of the express authorization already given and quoted above, Applicants wish to clarify that the rule subpart referenced in the Transmittal – 1.492(c) – should read –1.492(e). A copy of the Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US), in which the surcharge was referenced by the Patent Office, was attached to the Transmittal as required by the Patent Office. The copy quality of the language related to the surcharge in the Notification mistakenly appeared to reference 37 C.F.R. 1.492(c), rather than 37 C.F.R. 1.492(e). The correct subpart of 37 C.F.R. 1.492 relating to the surcharge, however, became apparent to Applicants' undersigned Representative after filing of the Transmittal. Accordingly, this Communication was subsequently generated and is being filed solely for the convenience of the Patent Office.

CERTIFICATE OF TRANSMISSION (37 C.F.R. §1.8)

I hereby certify that this paper, as well as those papers referenced herein, is being transmitted to the United States Patent and Trademark Office on the

Chily 15, 2002

Lisa M. McGeeban

Communication Serial No. 09/554,533 Page 2 of 2



Respectfully submitted,

Beeley et al.

Fax

BROBECK, PHLEGER & HARRISON LLP 12390 El Camino Real San Diego, CA 92130 Phone (858) 720-2584 (858) 720-2555

isa M. M. Lechan

Lisa M. McGeehan Reg. No. 41,185